- Vir Biotechnology (VIR, Financial) to present clinical data on hepatitis B and delta therapies at EASL Congress 2025.
- 24-week subgroup analysis from the Phase 2 SOLSTICE trial and MARCH study outcomes to be featured.
- Sessions will highlight the therapeutic potential of tobevibart and elebsiran drugs.
Vir Biotechnology, Inc. (VIR) is set to unveil promising clinical data from its ongoing research on hepatitis delta and hepatitis B at the European Association for the Study of the Liver (EASL) Congress 2025, scheduled for May 7-10 in Amsterdam. The data will include a 24-week subgroup analysis from the Phase 2 SOLSTICE trial in chronic hepatitis delta as well as findings from the MARCH Phase 2 study, which evaluated the efficacy of tobevibart and elebsiran, alone or in combination with pegylated interferon alfa, in chronic hepatitis B patients.
The SOLSTICE trial data focuses on the impact of baseline viral parameters and cirrhosis status on the virological and biochemical responses in participants treated with tobevibart and elebsiran. This analysis will be presented in a poster session on May 8. Additionally, the MARCH study results will be elaborated upon on May 9, illustrating the outcomes of 48 weeks of therapy followed by a 24-week post-treatment period with the drugs tobevibart (VIR-3434) and elebsiran (VIR-2218).
Tobevibart, a broadly neutralizing monoclonal antibody, and elebsiran, a small interfering RNA (siRNA), are both designed to target hepatitis B virus RNA transcripts and are currently under clinical development for treating patients with chronic hepatitis delta and chronic hepatitis B. Notably, earlier presentations have indicated that these combination therapies show promising potential in achieving hepatitis B surface antigen loss in patients with low baseline levels.
Vir Biotechnology, headquartered in San Francisco, continues to focus on developing solutions for serious infectious diseases and is actively advancing its portfolio targeting chronic hepatitis infections. The company's participation at the EASL Congress 2025 reaffirms its commitment to leveraging its scientific expertise in exploring transformative therapies.
